Molecular diagnostics
Testing capabilities that include PCR and other DNA/RNA-based methods used to help detect infectious diseases.
01 / MolecularExploring the work behind modern diagnosticsClearer insight.
Clearer insight.
Better informed care.
An independent look at STONE Diagnostics: its clinical laboratory services, company milestones, and the partnerships shaping its story.
Source-linked information, carefully curated
Clinical insight / 01
The company at a glanceWhere laboratory science
Where laboratory science
meets practical care.
STONE Diagnostics describes a service model designed for healthcare providers, patients, and a variety of testing environments.
Clinical laboratory services
Reference-laboratory offerings spanning areas such as chemistry, microbiology, hematology, and prescription drug monitoring.
02 / ClinicalProvider support
A company-described emphasis on personalized service, operational support, and flexible laboratory testing arrangements.
03 / ServiceService descriptions based on the official company overview. Availability and coverage may change.
Featured announcementA new chapter in
A new chapter in
advanced diagnostics.
In October 2025, Fibronostics announced its acquisition of Stone Clinical Laboratories, highlighting plans to strengthen U.S. laboratory infrastructure and advance development in liver and metabolic disease diagnostics.
The announcement describes how laboratory expertise and newer diagnostic technologies can complement one another.
October 2025Company developmentClinical innovation
Read the original announcement Selected coverage
View all news & press Stories worth following.
Industry publication covers Fibronostics acquisition
Intelligence360 reported on the Stone Clinical Laboratories transaction and outlined how the acquisition could support Fibronostics’ U.S. laboratory operations and liver-diagnostics strategy.
Intelligence360 · Business coverage↗Opens original sourceSTONE Diagnostics announces strategic partnership with Altus ACE
The announcement outlines a collaboration to provide preventive-care laboratory testing services to physicians and patients in the Altus ACE network.
Newswire · STONE announcement↗Opens original sourceFibronostics and STONE Diagnostics announce diagnostic collaboration
The companies announced a partnership supporting physician access to Fibronostics’ LIVERFASt liver-health assessment through STONE’s laboratory service platform.
PR Newswire · Fibronostics announcement↗Opens original sourceThese are linked company and partner announcements, not independently verified clinical outcome claims.
Selected milestones
A story of steady evolution.
2019
Accreditation announcement
Stone reports recognition by the College of American Pathologists.
2020
Public health collaboration
A Louisiana testing agreement is announced.
2021
New service partnerships
LumiraDx and ACS partnerships are announced.
2023–24
Broader collaborations
Fibronostics and Altus ACE partnerships are announced.
2025
Acquisition announcement
Fibronostics announces the Stone Clinical Laboratories acquisition.
Historical milestones are drawn from the linked releases in the news archive.
Go to the source
Visit official websiteExplore the full STONE Diagnostics story.
Visit the company directly for current services, patient information, and official updates.